Teva may buy more Mylan stock despite antitrust allegations

Harry Phillips

03 June 2015

Mylan's lucrative EpiPen is one reason Teva is pushing its $42 billion merger offer. (Credit: Roel Smart)

Subscribe to Global Competition Review

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

View full biography

Author

[email protected]

Safeties for safety: The Tipline for 30 January 2023
Lockheed Martin and Aerojet Rocketdyne announced they had abandoned their $4.4 billion merger during last year’s Super Bowl and Senator Elizabeth Warren is hoping for a repeat. The Democratic lawmaker is urging the Federal Trade Commission's offensive line to block Aerojet’s latest sale attempt and has also called on the agency to unwind a different military deal that it conditionally approved in 2018.
End of the FTC as we know it: The Tipline for 27 January 2023
Bridging troubled waters: The Tipline for 26 January 2023